Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Sepsis
 More »

  • Analytik Jena Acquires Sepsis Test Among SIRS-Lab Assets
    Analytik Jena will expand into the market for sepsis diagnostics by acquiring all assets ... concluding it wanted to continue the bankrupt company's initial success in sepsis testing. ...
    5-6-2013
  • Study Shows Eritoran Can Protect Against Lethal Flu Infection
    They chose Eritoran, the Eisai drug that recently failed to show reduced mortality in the ACCESS trial involving patients with severe sepsis. When administered therapeutically to ...
    4-30-2013
  • Triple Threat: New Dx Firm Forged from Three-Company Merger
    Current test products are intended for diagnosing bacterial and fungal sepsis, viral central nervous system infections, and bacterial bone and joint infections. Mobidiag-which ...
    4-12-2013
  • Toray Takes $5M Stake in Spectral Diagnostics
    "theranostic" product for sepsis, as well as for unspecified general corporate purposes. ... device designed to remove endotoxin, a cause of sepsis, from the bloodstream. ...
    3-7-2013
  • Xellia Enters Multidrug-Resistant Bacteria-Combating Collaboration
    , Klebsiella , Acinetobacter , and Enterobacter species, which can cause severe sepsis and septic shock. "These drugs have the potential to address the immediate global need ...
    2-26-2013
  • R&D Chiefs Out at Roche and AstraZeneca
    ... Another 2012 setback saw AZ and partner BTG halt development of the experimental drug AZD9773 or CytoFab(tm) for severe sepsis and/or septic shock, following its failure in a Phase ...
    1-16-2013
  • Nuron Biotech Acquires Another Vaccine
    N. meningitidis is a major cause of infectious disease worldwide that can lead to meningitis, sepsis, and pneumonia with a majority of cases occurring in children. Without ...
    12-10-2012
  • Deadly Sepsis: Are We Closer to Finding the Cause?
    Sepsis, a toxic, inflammatory response to infection, afflicts 20-30 million patients globally each year, according to the Global Sepsis Alliance. It is estimated that worldwide one ...
    11-13-2012
  • Trillium Licenses Cell-Free DNA Biomarker for Sepsis Dx
    biomarker for the development of a commercial IVD assay kit for diagnosing sepsis. ... within two years. "A prognostic assay for sepsis will represent a tremendous improvement ...
    10-10-2012
  • Nucleic Acid Sample-Prep Tools Break New Ground
    ... Taking on Sepsis The development of robotic systems for automating sample preparation and ... of microorganisms responsible for sepsis is low-on the order of one colony forming ...
    10-1-2012
  • Superbug Succumbs to Vitamin-Boosted Immune System
    However, while NAM has also been shown to improve survival of experimental mice with Gram-positive and Gram-negative sepsis, its potential role as an antimicrobial agent isn't well ...
    8-28-2012
  • AZ Names Roche Executive as New CEO
    this month, AZ and partner BTG halted development of the experimental drug AZD9773 or CytoFab(tm) for severe sepsis and/or septic shock, following its failure in a Phase IIb trial. ...
    8-28-2012
  • Another Day, Another AZ Failure
    of an experimental drug for severe sepsis and/or septic shock, following its ... AstraZeneca, BTG halt work on sepsis drug following disappointing results in a ...
    8-8-2012
  • Immunexpress, Debiopharm, and Biocartis to Advance SeptiCyte...
    royalty-bearing license for SeptiCyte® Triage for sepsis diagnosis and prognosis. ... or upon hospital admission to identify sepsis early, differentiate sepsis from other ...
    6-19-2012
  • Biomarker Diagnostics Firm Astute Raises $40.4M in Series C Fundraisin...
    conditions that require rapid diagnosis and risk assessment, and disorders including abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. ...
    6-7-2012
  • More »

    Journal Articles

  • Diagnostic Criteria, Clinical Features, and Incidence of Thyroid...
    Takashi Akamizu, Tetsurou Satoh, Osamu Isozaki, Atsushi Suzuki, Shu Wakino, Tadao Iburi, Kumiko Tsuboi, Tsuyoshi Monden, Tsuyoshi Kouki, Hajime Otani, Satoshi Teramukai, Ritei Uehara, Yosikazu Nakamura, Masaki Nagai, Masatomo Mori, for the Japan Thyroid Association
    Thyroid
    common cause of death in TS1 and TS2, followed by CHF, respiratory failure, arrhythmia, disseminated intravascular coagulation, GI perforation, hypoxic brain syndrome, and sepsis. ...
  • Sepsis from Spontaneous Vesicocutaneous Fistula
    Emanuel Cavazzoni, Walter Bugiantella, Luigina Graziosi, Maria Silvia Franceschini, Francesco Cantarella, Annibale Donini
    Surgical Infections
    Sepsis from Spontaneous Vesicocutaneous Fistula Surgical Infections
  • Disseminated Nocardia farcinica : Literature Review and Fatal...
    Jonathan M. Budzik, Mojgan Hosseini, Alexander C. Mackinnon, Jerome B. Taxy
    Surgical Infections
    Methods: Review of the recent literature and description of a immunocompetent patient with no known risk factors who contracted fatal N. farcinica sepsis. Results: Positive ...
  • Fascia-to-Fascia Closure with Abdominal Topical Negative Pressure...
    Pietro Padalino, Gianlorenzo Dionigi, Giulio Minoja, Giulio Carcano, Francesca Rovera, Luigi Boni, Renzo Dionigi
    Surgical Infections
    All patients had abdominal compartment syndrome and a sepsis source that was difficult to control. Results: All patients survived. The mean duration of open abdomen was 22.7 days ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll